Generating knowledge and providing greater understanding so that you can make better decisions.

With rigorous scientific practices and deep industry experience, we help you gather evidence, analyze results, increase understanding, and gain greater clarity to help reveal the benefits, risks, value, and potential of your products.
The power of knowledge. The value of understanding.

Sat 5/20
8:00a – 12:00p Short Course: Hauber AB, Marshall DA - Introduction to conjoint analysis

Sun 5/21
8:00a – 12:00p Short Course: Mauskopf JA, Mullins CD, Earnshaw SR - Budget impact analysis I: a 6-step approach
8:00a – 12:00p Short Course: Wolowacz S, Briggs A, Lloyd A, Doward L - Collecting health-state utility estimates for economic models in clinical studies
10:00 – 5:00p Short Course: Earnshaw SR, Brogan AJ, Brodkorb TH - Budget impact analysis II: applications and design issues

Mon 5/22
Poster Session I
8:30a – 2:00p
Poster PIN14: Talbird SE, La EM, Poston SA, Hogeza CS - A budget-impact analysis of quadrivalent influenza vaccine use in the United States
Poster PIN81: Lindsay B, Groom H, Nalleyu A, Guzman-Cottrell J, Kurosky S - Impact of 9-valent human papillomavirus vaccine on vaccination of adolescents and young adults in the Pacific Northwest

Poster Session II
3:45 – 7:45p
Poster PCN69: Gonzalez JM, Christodouloupolou A, Hechmati G, Mange B, Garawin T - Patient preferences regarding tradeoffs between efficacy and adverse events for metastatic colorectal cancer treatments
Poster PCN171: Mansfield CA, Boeri M, Sutphin J, Reyes C, Masaque AI, Li J - How can we assess the impact of cost on patient treatment preferences in CLL treatment?
Poster PSS12: Graham CN, McBride D, Miles L, Gilleoteau I, O’Neill CB, Neidhardt K, Augustin M - Cost-effectiveness of secukinumab in moderate to severe psoriasis compared with other biologics in Germany
Poster PSS15: Augustin M, Graham CN, Miles L, Gilleoteau I, O’Neill CB, Neidhardt K, McBride D - A cost-per responder analysis of secukinumab compared with ustekinumab through 52 weeks in Germany: results from the CLEAR study of patients with moderate to severe psoriasis

Tues 5/23
Poster Session III
8:30a – 2:00p
Poster PDB38: Bell K, Meyers J, Candrilli SD, Ajmera MR - Characteristics and costs of patients with type 2 diabetes augmenting metformin with dapagliflozin versus glimepiride: an analysis of commercial claims data
Poster PDB55: McLeod L, Sirkica MV, Davenport E, Sweeney CT, Joshi AV - The impact of GLP-1 induced nausea and vomiting on work productivity and health-related quality of life in patients with T2DM
Poster PDB68: McLeod L, Sirkica MV, Qin S, Joshi AV, Sweeney CT, Blum SI - Psychometric evaluation of the NV questionnaire in patients with T2DM receiving a GLP-1 agonist
Poster PND25: Ajmera M, Goyal RK, Davis KL - Incremental economic burden of cardiometabolic disorders among patients with epilepsy
Poster PSY125: Goyal RK, Ajmera MR, Davis KL - Recent trends in emergency department visits resulting from unintentional overdose of non-opioid analgesics, antipyretics, and antihypertumics in the United States

Poster Session IV
3:45 – 7:45p
Poster PCV18: Nagar SP, Fox KM, Rane PP, Beabrun A, Qian Y, Inomata H, Davis KL, Meyers J, Kajinami K - Incidence of cardiovascular events among secondary prevention patients treated with statins or ezetimibe in Japan


Wed 5/24
Poster Session V
8:30a – 1:30p
Poster PHS62: Dave I, Nagar SP, Arif AA, Laditka SB, Huber LR - Association between asthma medication use and total healthcare costs among patients with asthma
Poster PHS100: Park J, Covert D, Farshid C, Brubaker M, Martin SA, Lewis S, DeMuro C - Development of an eye drop comfort measure for topical ocular drop application
Poster PRM84: Johnson KD, Jiang Y, Weiss T, Graham J - Herpes zoster vaccine effectiveness and waning of effectiveness